Phantomics said Tuesday that the company has received a medical device marketing authorization from the Thai Food and Drug Administration (TFDA) for its non-invasive cardiomyopathy diagnostic solution, Myomics.

Myomics, launched by Phanthomics in 2020, is a service that non-invasively extracts dozens of imaging biomarkers using cardiac MRI to diagnose myocardial diseases, including heart failure, myocarditis, and amyloidosis, the company said.

Recognized for its innovative technology, Myomics is used in high-end general hospitals in Korea, Japan, China, Taiwan, and Singapore. It also has won approval from the U.S. Food and Drug Administration. Besides, after completing sales contracts with medical device distributors in Southeast Asia and South America, the company tries to obtain local medical device licenses.

"We are pleased to introduce our AI software to the Thai medical field through this TFDA certification," Phantomics CEO Kim Pan-ki said.